2025 ASCO Annual Meeting

CAR T-cell therapy has achieved a significant improvement in progression-free survival for advanced gastric and gastroesophageal junction cancer.

Treating patients with HER2-positive metastatic gastric cancer with trastuzumab deruxtecan rather than ramucirumab plus paclitaxel leads to better survival outcomes.

The MATTERHORN trial has shown that adding durvalumab to perioperative FLOT boosts event-free survival in people with gastric or gastroesophageal junction cancer.

Encorafenib and cetuximab combined with chemotherapy improves progression-free and overall survival in BRAF V600E-mutated metastatic colorectal cancer.

Swapping first-line aromatase inhibitor treatment with camizestrant at emergence of ESR1 mutations benefits patients with HR-positive, HER2-negative advanced breast cancer.

Vepdegestrant, a proteolysis-targeting chimera, achieves longer progression-free survival versus fulvestrant as a treatment for ESR1-mutated, HER2-negative, advanced breast cancer.

Dose reduction of lorlatinib has a positive effect on the occurrence of side effects, allowing patients to continue treatment for long periods of time.

Administering immune checkpoint inhibitors earlier in the day leads to better outcomes in patients with NSCLC, compared with administration later in the day.

The addition of perioperative pembrolizumab to standard treatment for resectable locally advanced squamous cell carcinoma of the head and neck significantly extends event-free survival.

Combining pembrolizumab with sacituzumab govitecan rather than chemotherapy achieves better progression-free survival in untreated patients with PD-L1-positive triple-negative breast cancer.

AI support improves the assessment of HER2 expression in breast cancer, increasing accuracy of categorizing tumors from 90.1% without AI assistance to 95.0% with support.